Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports-Reference-Cited by-同舟云学术

Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6 mg/kg of recombinant tissue-type plasminogen activator. Case reports

Published:2018-10 Issue: Volume:393 Page:24-26
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Plastino Massimiliano,Bosco Domenico,Giofrè Laura,Cristiano Dario,Galati Franco,Postorino Paolo,Consoli Arturo,Fava Antonietta,Consoli Domenico

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference13 articles.

1. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism;Granger;Circulation,2012

2. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature;Dentali;Circulation,2012

3. Tissue plasminogen activator for acute ischemic stroke;The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group;NEJM,1995

4. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

5. Management of acute stroke in patients taking novel oral anticoagulants;Hankey;Int. J. Stroke,2014

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants;Stroke;2020-02

2. Alteplase/rivaroxaban;Reactions Weekly;2018-09